|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TLK2 |
Gene summary for TLK2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TLK2 | Gene ID | 11011 |
| Gene name | tousled like kinase 2 | |
| Gene Alias | HsHPK | |
| Cytomap | 17q23.2 | |
| Gene Type | protein-coding | GO ID | GO:0001672 | UniProtAcc | Q86UE8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 11011 | TLK2 | HTA11_3410_2000001011 | Human | Colorectum | AD | 3.18e-13 | -5.25e-01 | 0.0155 |
| 11011 | TLK2 | HTA11_866_3004761011 | Human | Colorectum | AD | 1.73e-06 | -4.26e-01 | 0.096 |
| 11011 | TLK2 | HTA11_8622_2000001021 | Human | Colorectum | SER | 4.43e-02 | -5.96e-01 | 0.0528 |
| 11011 | TLK2 | HTA11_7696_3000711011 | Human | Colorectum | AD | 7.67e-09 | -4.17e-01 | 0.0674 |
| 11011 | TLK2 | HTA11_6818_2000001021 | Human | Colorectum | AD | 8.39e-03 | -5.00e-01 | 0.0588 |
| 11011 | TLK2 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 7.10e-12 | -4.87e-01 | 0.294 |
| 11011 | TLK2 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 1.41e-11 | 7.63e-01 | 0.281 |
| 11011 | TLK2 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.28e-06 | -3.86e-01 | 0.3005 |
| 11011 | TLK2 | F007 | Human | Colorectum | FAP | 4.14e-03 | -3.20e-01 | 0.1176 |
| 11011 | TLK2 | A002-C-010 | Human | Colorectum | FAP | 2.04e-02 | -2.33e-01 | 0.242 |
| 11011 | TLK2 | A001-C-207 | Human | Colorectum | FAP | 1.43e-04 | -3.15e-01 | 0.1278 |
| 11011 | TLK2 | A015-C-203 | Human | Colorectum | FAP | 5.79e-31 | -4.22e-01 | -0.1294 |
| 11011 | TLK2 | A015-C-204 | Human | Colorectum | FAP | 2.35e-09 | -3.33e-01 | -0.0228 |
| 11011 | TLK2 | A014-C-040 | Human | Colorectum | FAP | 3.56e-05 | -3.44e-01 | -0.1184 |
| 11011 | TLK2 | A002-C-201 | Human | Colorectum | FAP | 6.92e-20 | -4.24e-01 | 0.0324 |
| 11011 | TLK2 | A002-C-203 | Human | Colorectum | FAP | 1.51e-04 | -2.36e-01 | 0.2786 |
| 11011 | TLK2 | A001-C-119 | Human | Colorectum | FAP | 1.11e-09 | -3.90e-01 | -0.1557 |
| 11011 | TLK2 | A001-C-108 | Human | Colorectum | FAP | 3.21e-19 | -3.45e-01 | -0.0272 |
| 11011 | TLK2 | A002-C-205 | Human | Colorectum | FAP | 3.18e-26 | -4.21e-01 | -0.1236 |
| 11011 | TLK2 | A001-C-104 | Human | Colorectum | FAP | 8.62e-07 | -3.07e-01 | 0.0184 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004217719 | Oral cavity | OSCC | negative regulation of protein catabolic process | 77/7305 | 121/18723 | 3.49e-08 | 6.64e-07 | 77 |
| GO:00714788 | Oral cavity | OSCC | cellular response to radiation | 109/7305 | 186/18723 | 4.54e-08 | 8.45e-07 | 109 |
| GO:007147917 | Oral cavity | OSCC | cellular response to ionizing radiation | 49/7305 | 72/18723 | 5.59e-07 | 8.13e-06 | 49 |
| GO:004586120 | Oral cavity | OSCC | negative regulation of proteolysis | 181/7305 | 351/18723 | 1.01e-06 | 1.37e-05 | 181 |
| GO:00182098 | Oral cavity | OSCC | peptidyl-serine modification | 175/7305 | 338/18723 | 1.09e-06 | 1.46e-05 | 175 |
| GO:001810510 | Oral cavity | OSCC | peptidyl-serine phosphorylation | 164/7305 | 315/18723 | 1.51e-06 | 1.99e-05 | 164 |
| GO:200005919 | Oral cavity | OSCC | negative regulation of ubiquitin-dependent protein catabolic process | 35/7305 | 48/18723 | 1.93e-06 | 2.47e-05 | 35 |
| GO:190336317 | Oral cavity | OSCC | negative regulation of cellular protein catabolic process | 49/7305 | 75/18723 | 3.49e-06 | 4.15e-05 | 49 |
| GO:00324359 | Oral cavity | OSCC | negative regulation of proteasomal ubiquitin-dependent protein catabolic process | 26/7305 | 35/18723 | 2.40e-05 | 2.26e-04 | 26 |
| GO:190305117 | Oral cavity | OSCC | negative regulation of proteolysis involved in cellular protein catabolic process | 41/7305 | 64/18723 | 4.31e-05 | 3.71e-04 | 41 |
| GO:00105075 | Oral cavity | OSCC | negative regulation of autophagy | 51/7305 | 85/18723 | 7.08e-05 | 5.62e-04 | 51 |
| GO:00103326 | Oral cavity | OSCC | response to gamma radiation | 36/7305 | 56/18723 | 1.12e-04 | 8.24e-04 | 36 |
| GO:19017998 | Oral cavity | OSCC | negative regulation of proteasomal protein catabolic process | 31/7305 | 49/18723 | 5.04e-04 | 2.95e-03 | 31 |
| GO:00714809 | Oral cavity | OSCC | cellular response to gamma radiation | 21/7305 | 31/18723 | 1.13e-03 | 5.75e-03 | 21 |
| GO:000632510 | Oral cavity | OSCC | chromatin organization | 190/7305 | 409/18723 | 1.17e-03 | 5.97e-03 | 190 |
| GO:001810514 | Oral cavity | EOLP | peptidyl-serine phosphorylation | 84/2218 | 315/18723 | 3.32e-13 | 1.05e-10 | 84 |
| GO:001820914 | Oral cavity | EOLP | peptidyl-serine modification | 87/2218 | 338/18723 | 1.07e-12 | 2.46e-10 | 87 |
| GO:001049825 | Oral cavity | EOLP | proteasomal protein catabolic process | 108/2218 | 490/18723 | 7.79e-11 | 9.51e-09 | 108 |
| GO:004217626 | Oral cavity | EOLP | regulation of protein catabolic process | 90/2218 | 391/18723 | 2.92e-10 | 2.58e-08 | 90 |
| GO:004316125 | Oral cavity | EOLP | proteasome-mediated ubiquitin-dependent protein catabolic process | 92/2218 | 412/18723 | 9.87e-10 | 6.96e-08 | 92 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TLK2 | SNV | Missense_Mutation | novel | c.1820N>C | p.Gly607Ala | p.G607A | Q86UE8 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
| TLK2 | SNV | Missense_Mutation | c.1219N>C | p.Glu407Gln | p.E407Q | Q86UE8 | protein_coding | deleterious(0.01) | benign(0.371) | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| TLK2 | SNV | Missense_Mutation | c.1730N>T | p.Ala577Val | p.A577V | Q86UE8 | protein_coding | deleterious(0) | probably_damaging(0.926) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TLK2 | SNV | Missense_Mutation | c.1658A>G | p.Asp553Gly | p.D553G | Q86UE8 | protein_coding | deleterious(0) | possibly_damaging(0.685) | TCGA-D8-A1XC-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
| TLK2 | SNV | Missense_Mutation | novel | c.93N>G | p.Asn31Lys | p.N31K | Q86UE8 | protein_coding | deleterious_low_confidence(0.02) | benign(0.007) | TCGA-PE-A5DC-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| TLK2 | SNV | Missense_Mutation | novel | c.1703G>A | p.Arg568Gln | p.R568Q | Q86UE8 | protein_coding | deleterious(0) | probably_damaging(0.909) | TCGA-UL-AAZ6-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | herceptin | SD |
| TLK2 | SNV | Missense_Mutation | rs200158456 | c.127N>A | p.Gly43Arg | p.G43R | Q86UE8 | protein_coding | deleterious_low_confidence(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| TLK2 | SNV | Missense_Mutation | novel | c.1864G>T | p.Asp622Tyr | p.D622Y | Q86UE8 | protein_coding | deleterious(0) | probably_damaging(0.928) | TCGA-C5-A8XI-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | SD |
| TLK2 | SNV | Missense_Mutation | c.857G>C | p.Arg286Thr | p.R286T | Q86UE8 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-JX-A3Q0-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
| TLK2 | SNV | Missense_Mutation | c.1801N>C | p.Val601Leu | p.V601L | Q86UE8 | protein_coding | tolerated(0.24) | probably_damaging(0.981) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 11011 | TLK2 | DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, ENZYME | GO6983 | 27694828 | ||
| 11011 | TLK2 | DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, ENZYME | GF109203X | 27694828 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |